Advanced search

News (101)

Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism	14/09/23	AQ
Soleno Therapeutics : Submission of Matters to a Vote of Security Holders - Form 8-K	27/05/23	PU
SOLENO THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)	26/05/23	AQ
Transcript : Soleno Therapeutics, Inc. - Shareholder/Analyst Call	25/05/23
Nykode Therapeutics : Nomination Committee Proposal	20/04/23	PU
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon PTH in Adult Patients with Hypoparathyroidism	15/11/22	AQ
Transcript : Ascendis Pharma A/S - Special Call	14/11/22
Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines Agency for TransCon™ PTH in Adult Patients with Hypoparathyroidism	14/11/22	AQ
Transcript : Ascendis Pharma A/S, Q3 2022 Earnings Call, Nov 02, 2022	02/11/22
FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon PTH in Adult Patients with Hypoparathyroidism	01/11/22	AQ
FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism	31/10/22	AQ
Ascendis Pharma A/S : Notice to convene Extraordinary General Meeting - Form 6-K	21/10/21	PU
Ascendis Pharma A/S Appoints Birgitte Volck as the Senior Vice President & Head of Clinical Development & Medical Affairs, Endocrinology Rare Diseases and Resigns from the Nominating and Corporate Governance Committee of the Company’S Board of Directors and Board of Directors	14/06/21	CI
Vaccibody : Grant of Restricted Share Units and Share Options	03/06/21	AQ
Transcript : Soleno Therapeutics, Inc. - Shareholder/Analyst Call	01/06/21
Vaccibody AS : appoints Dr. Volck, M.D., Ph.D. as new member of the Board	05/05/21	AQ
Ascendis Pharma A/S : Election of Board Members 6. Election of State-authorized Public Auditor 7. Any proposals from the Board of Directors and/or Shareholders	30/04/21	PU
AVROBIO : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	06/08/20	AQ
SOLENO THERAPEUTICS INC : Change in Directors or Principal Officers, Results of Operations and Financial Condition (form 8-K)	19/05/20	AQ
AVROBIO : Reports 1Q 2020 Financial Results and Provides Business Update	07/05/20	BU
AVROBIO : to Present New Clinical and Preclinical Data at Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 12-15, 2020	05/05/20	BU
Soleno Therapeutics, Inc. Announces Executive Changes	20/04/20	CI
Transcript : AVROBIO, Inc. Presents at 16th Annual WORLDSymposium 2020, Feb-10-2020 through Feb-13-2020	10/02/20
AVROBIO : Announces Clinical Data Presentation and Multiple Events at WORLDSymposium 2020	05/02/20	AQ
AVROBIO : Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020	04/02/20	BU
AVROBIO Announces Clinical Data Presentation and Multiple Events at WORLDSymposium™ 2020	04/02/20	CI
AVROBIO : Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher Disease	24/10/19	BU
AVROBIO : Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis	08/10/19	BU
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results	07/08/19	GL
Transcript : AVROBIO, Inc. - Special Call	15/07/19
AVROBIO : Announces 87% Substrate Reduction in First Kidney Biopsy and Additional Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease	15/07/19	BU
Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors	12/06/19	GL
Soleno Therapeutics Appoints Birgitte Volck to its Board of Directors	12/06/19	CI
AVROBIO : Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy	26/04/19	BU
AVROBIO, Inc. : Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update	25/03/19	BU
Transcript : AVROBIO, Inc. - Shareholder/Analyst Call	06/02/19
AVROBIO : Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease	06/02/19	PU
AVROBIO, Inc. : Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease	06/02/19	BU
AVROBIO, Inc. Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	18/12/18	GL
AVROBIO, Inc. Expands and Strengthens Leadership Team with Four Senior Management Hires	18/12/18	GL
AVROBIO, Inc. Announces Management Changes	18/12/18	CI
Wilson Therapeutics : Apr 11, 2018 Statement by the Independent Committee of the Board of Directors of Wilson Therapeutics in relation to the public offer from Alexion Read more	11/04/18	PU
Wilson Therapeutics : Feb 21, 2018 Wilson Therapeutics AB (Publ) Year-End Report 2017 Read more	21/02/18	PU
Wilson Therapeutics : Nov 23, 2017 Wilson Therapeutics AB (publ) Interim Report January 1–September 30, 2017 Read more	23/11/17	PU
Wilson Therapeutics : Aug 24, 2017 Wilson Therapeutics AB (publ) Interim Report January 1 – June 30, 2017 Read more	24/08/17	PU

123NextSee all

Insiders

Birgitte Volck

Currently, Birgitte Volck holds the position of SVP, Head-Clinical Development & Medical Affairs at Ascendis Pharma A. Dr. Volck is also on the board of Soleno Therapeutics, Inc. and Vaccibody AS. Dr. Volck previously occupied the position of Head-Research & Development at GlaxoSmithKline Plc, Chief Medical Officer & Senior VP-Development at Swedish Orphan Biovitrum AB, President-Research & Development at Avrobio, Inc., Director-Executive Development at Amgen, Inc., Director-Nordic Medical & Project Director at Genzyme Danmark and Head-Clinical Development & Medical Affairs at Pharmexa A. Birgitte Volck received a doctorate from the University of Copenhagen.

Birgitte Rønnow has founded Terranol A in 2007, where she currently holds the title of Chief Executive Officer.
She previously worked as a Principal at DuPont Nutrition Biosciences ApS.
Dr. Rønnow earned a doctorate degree from the University of Copenhagen in 1992.

No results for this search